Pharsight

1. List of Tukysa drug patents

Application	Filing Date	Opposition Party	Legal Status
EP18162971A	2021-09-01	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP18162971A	2021-09-01	Sandoz AG	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7452895	SEAGEN	Quinazoline analogs as receptor tyrosine kinase inhibitors	Nov, 2024 (1 year, 5 months from now)
US8648087	SEAGEN	N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases	Apr, 2031 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9693989	SEAGEN	N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases	May, 2027 (3 years from now)
US9457093	SEAGEN	Solid dispersions of a ERB2 (HER2) inhibitor	Oct, 2032 (9 years from now)
US11504370	SEAGEN	NA	Mar, 2033 (9 years from now)
US11207324	SEAGEN	Treatment of HER2 positive cancers	Apr, 2038 (14 years from now)

Do you want to check out TUKYSA patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jan 19, 2030
New Chemical Entity Exclusivity (NCE)	Apr 17, 2025
New Indication (I)	Jan 19, 2026

NCE-1 date: 2024-04-17

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer; Combination treatment of colorectal cancer including ras wild-type her2 (erbb2)-positive or -overexpressing...

Dosage: TABLET;ORAL